Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2009 (First Quarter of Fiscal Year 2010)
Business Overview: AngioDynamics designs, develops, manufactures, and markets innovative medical devices for minimally invasive, image-guided procedures. The company operates three reportable segments: Peripheral Vascular, Access, and Oncology/Surgery. Products include devices for treating peripheral vascular disease (PVD) and local oncology therapy options such as radiofrequency ablation (RFA) and irreversible electroporation (IRE).
Key Financial Metrics
| Metric | Q1 FY2010 (Aug 31, 2009) | Q1 FY2009 (Aug 31, 2008) |
|---|---|---|
| Net Sales | $50,092,000 | $44,323,000 |
| Gross Profit | $30,132,000 (60.2% margin) | $27,457,000 (61.9% margin) |
| Operating Income | $3,575,000 (7.1% margin) | $3,822,000 (8.6% margin) |
| Net Income | $2,111,000 | $2,211,000 |
| Earnings Per Share (Diluted) | $0.09 | $0.09 |
| Cash and Cash Equivalents | $32,168,000 | $18,518,000 (End of period prior year) |
| Total Cash, Equivalents & Marketable Securities | $68,756,000 | $68,187,000 (May 31, 2009) |
| Total Debt | $6,990,000 | $7,075,000 (May 31, 2009) |
| Net Cash from Operating Activities | $1,139,000 | $1,671,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% ($5.8 million) year-over-year. Growth was driven by increased unit sales of LC Bead (embolization), laser ablation products (Peripheral Vascular), SmartPort CT (Access), and Benephit renal infusion systems (acquired via FlowMedica).
- Margin Compression: Gross profit margin decreased from 61.9% to 60.2% due to sales mix changes, competitive pricing pressures, material cost increases, and labor utilization variances.
- Expense Increases:
- R&D: Increased 22% to $4.8 million (9.7% of sales), primarily due to engineering personnel supporting IRE development ($1.8 million spent on IRE).
- Sales & Marketing: Increased 17% to $15.4 million (30.7% of sales) due to expanded sales territories and IRE marketing activities.
- G&A: Decreased 6% to $4.1 million due to settled litigation costs and reduced integration expenses from the prior year.
- Segment Performance:
- Peripheral Vascular: Sales up 14% to $21.1 million; Operating income up to $2.49 million.
- Access: Sales up 3% to $16.2 million; Operating income declined to $1.59 million.
- Oncology/Surgery: Sales up 25% to $12.8 million; Operating loss narrowed to $(0.5) million from $(1.0) million.
Guidance, Outlook, and Risks
- CEO Transition: Completed in Q3 FY2009. A $2.9 million provision was recorded in G&A for transition costs; approximately $660,000 remained in accrued liabilities as of August 31, 2009.
- Acquisitions:
- FlowMedica (Jan 2009): Acquired Benephit product line for ~$1.75 million cash plus contingent payments.
- Oncobionic (May 2008): Acquired IRE technology. Remaining $5.0 million of purchase price due November 2009.
- Outlook: Management expects R&D expenditures to approach 10% of net sales in FY2010 due to IRE investment. The company believes current cash and investment balances ($68.8 million) are sufficient for the next 12 months but may require additional financing for significant future acquisitions.
- Liquidity & Debt: Total debt is approximately $7.0 million, secured by facility expansions. The company holds $1.85 million in auction rate securities (ARS) that have failed auctions; however, issuers are current on interest payments.
- Legal Proceedings: Filed a patent infringement lawsuit against Vascular Solutions, Inc. regarding endovenous laser treatment patents. Management does not expect pending litigation to have a material adverse effect.
- Real Estate: Entered a lease agreement in July 2009 for a new 52,500 sq. ft. corporate headquarters in Latham, NY, with targeted occupancy in March 2010.
Investor Verification Checklist
- Auction Rate Securities: Verify the liquidity status and fair value of the $1.85 million investment in failed auction rate securities.
- IRE Commercialization: Assess the progress and revenue contribution of the NanoKnife/IRE technology, which currently represents a small fraction of sales but drives significant R&D spend.
- Margin Trends: Monitor gross margin stability given the noted pressures from competition and material costs.
- Debt Covenants: Review compliance with financial covenants related to the $7 million facility financing (fixed charge and interest coverage).
- Contingent Liabilities: Track the $5.0 million remaining payment due to Oncobionic in November 2009 and potential royalty obligations.